On the role of plasminogen activator inhibitor‐1 in adipose tissue development and insulin resistance in mice
Open Access
- 9 June 2005
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (6) , 1174-1179
- https://doi.org/10.1111/j.1538-7836.2005.01390.x
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Pleiotropic functions of plasminogen activator inhibitor-1Journal of Thrombosis and Haemostasis, 2005
- Characterization and comparative evaluation of a structurally unique PAI‐1 inhibitor exhibiting oral in‐vivo efficacyJournal of Thrombosis and Haemostasis, 2004
- Tiplaxtinin, a Novel, Orally Efficacious Inhibitor of Plasminogen Activator Inhibitor-1: Design, Synthesis, and Preclinical CharacterizationJournal of Medicinal Chemistry, 2004
- Effect of heterozygous PPARγ deficiency and TZD treatment on insulin resistance associated with age and high-fat feedingAmerican Journal of Physiology-Endocrinology and Metabolism, 2003
- Effect of Glucose Tolerance Status on PAI‐1 Plasma Levels in Overweight and Obese SubjectsObesity Research, 2002
- Disruption of the plasminogen activator inhibitor‐1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob miceThe FASEB Journal, 2001
- Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular DiseaseDiabetes, 1997
- Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeistyNature Medicine, 1996
- Some Coronary Risk Factors Related to the Insulin Resistance Syndrome and Treatment With GemfibrozilCirculation, 1995
- Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosisDiabetologia, 1991